Sam Brusco, Associate Editor05.04.22
SeaSpine has launched its OsteoTorrent and OsteoTorrent C Accell demineralized bone matrix (DBM) putties, which are packaged and sterilized in a dry state. The putties aim to improve osteoinductive potential and shelf life, and let surgeons reconstitute with saline, blood, or bone marrow aspirate.
“I am proud to announce the launch of a new family of DBM Putty products,” Dr. Frank Vizesi, SeaSpine’s chief scientific officer told the press. “OsteoTorrent and OsteoTorrent C were internally developed, leveraging knowledge gained during development of OsteoStrand Plus of the importance of driving moisture out of a DBM to increase its bone forming potential. We recognized an opportunity to improve our DBM putty products and were able to rapidly implement a new process through our in-house manufacturing facility in Irvine, California.”
Dr. Gerard Girasole, a Board-Certified Orthopaedic Surgeon who serves as the chief of Spine Orthopaedics and medical co-director of the new Connecticut Orthopaedic Institute at St. Vincent’s Medical Center Hartford Health, performed the first surgeries with OsteoTorrent earlier this month. “OsteoTorrent provides the same outstanding handling as Evo3: it packs into any gaps and ensures the graft does not migrate, with the additional benefits of a dry DBM.”
“This launch is a major milestone that allows SeaSpine to upgrade our largest product family as a company, and further strengthens our position as the #2 DBM supplier in the U.S.,” said Tyler Lipschultz, senior VP, Orthobiologics for SeaSpine. “Importantly, it further demonstrates our R&D team’s scientific discipline to isolate, test, and optimize individual elements to deliver better, more cost-effective DBMs that compete favorably with many of the more expensive bone grafting alternatives. Ultimately, we are executing on our strategy to deliver scalable and sustainable growth through clinical value.”
“I am proud to announce the launch of a new family of DBM Putty products,” Dr. Frank Vizesi, SeaSpine’s chief scientific officer told the press. “OsteoTorrent and OsteoTorrent C were internally developed, leveraging knowledge gained during development of OsteoStrand Plus of the importance of driving moisture out of a DBM to increase its bone forming potential. We recognized an opportunity to improve our DBM putty products and were able to rapidly implement a new process through our in-house manufacturing facility in Irvine, California.”
Dr. Gerard Girasole, a Board-Certified Orthopaedic Surgeon who serves as the chief of Spine Orthopaedics and medical co-director of the new Connecticut Orthopaedic Institute at St. Vincent’s Medical Center Hartford Health, performed the first surgeries with OsteoTorrent earlier this month. “OsteoTorrent provides the same outstanding handling as Evo3: it packs into any gaps and ensures the graft does not migrate, with the additional benefits of a dry DBM.”
“This launch is a major milestone that allows SeaSpine to upgrade our largest product family as a company, and further strengthens our position as the #2 DBM supplier in the U.S.,” said Tyler Lipschultz, senior VP, Orthobiologics for SeaSpine. “Importantly, it further demonstrates our R&D team’s scientific discipline to isolate, test, and optimize individual elements to deliver better, more cost-effective DBMs that compete favorably with many of the more expensive bone grafting alternatives. Ultimately, we are executing on our strategy to deliver scalable and sustainable growth through clinical value.”